Novel peptide-based strategy to inhibit deleterious TNF signaling in nephrotoxic nephritis
基于肽的新型策略抑制肾毒性肾炎中有害的 TNF 信号传导
基本信息
- 批准号:9296123
- 负责人:
- 金额:$ 22.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-08-01 至 2018-06-30
- 项目状态:已结题
- 来源:
- 关键词:Acute GlomerulonephritisAdverse effectsAffectAlbuminuriaAnti-Bacterial AgentsAnti-Inflammatory AgentsAnti-inflammatoryAntibodiesBacterial InfectionsBindingBiological PreservationCCL2 geneCellsCollagenComplexConduct Clinical TrialsCoupledCouplingDevelopmentDinoprostoneDiseaseDisease ProgressionEdemaEndothelial CellsEpithelialEpitopesEtiologyFunctional disorderGenerationsGlomerular Filtration RateGlomerulonephritisGoalsHumanImmuneImmune Complex GlomerulonephritisImmunosuppressive AgentsImpairmentIn VitroInfectionInfiltrationInflammationInflammation MediatorsInflammatoryInjuryInterleukin-6KidneyKidney DiseasesKidney FailureKnock-inKnock-in MouseKnowledgeLeadLectinLeukocytesLigand BindingLinkMAPK14 geneMediatingMediator of activation proteinMethodsModelingMusNephritisNephrotoxicOnset of illnessOutcomeParticipantPathogenesisPathway interactionsPatientsPeptidesPharmaceutical PreparationsPhasePhysiologicalPlayPredispositionPropertyProteinuriaReagentRecruitment ActivityRenal functionRenal glomerular diseaseRiskRoleSerumSignal TransductionSteroidsStressTNF geneTNFRSF1A geneTestingTherapeuticTherapeutic InterventionTimeTransgenic MiceTumor Necrosis Factor ReceptorWestern BlottingWild Type Mousebasecaveolin 1chemokinecomparative efficacyconventional therapycytokineexperimental studyimprovedin vivomacrophagemimeticsmitogen-activated protein kinase p38mutantnephrotoxicitynovelnovel therapeutic interventionnovel therapeuticsoverexpressionpeptide drugpodocytepreventpromoterprotective effectprotective efficacypublic health relevancereceptorrepairedsynaptopodintargeted treatmenttherapeutic target
项目摘要
DESCRIPTION (provided by applicant): The early stage of nephrotoxic serum (NTS)-induced nephritis (NTN) in mice is characterized by excessive inflammation and glomerular barrier dysfunction and represents a good model for human acute glomerulonephritis (GN). Glomerular endothelial and epithelial compartments represent attractive targets for early therapeutic intervention, due to their crucial roles in the recruitment of leukocytes, proteinuria and progressive renal failure. Current therapies aiming to treat or prevent progression of the disease are insufficient and limited, stressing the need for novel therapeutic approaches that control inflammation associated with GN. In this context, the cytokine TNF is an ideal target, since it is critically involved in both human GN and in murine NTN. Unfortunately, attempts to blunt TNF binding to its receptors for the treatment of GN were met with unexpected side effects, including increased risk for bacterial infection. Therefore, therapies that specifically target the deleterios effects of TNF, but leave its beneficial effects intact are desirable. Our preliminary studies indicate that the TIP peptide, which mimics TNF's lectin-like domain and which does not interfere with the ligand's binding to its receptors, interferes with at least two pathways importat in podocyte and glomerular endothelial cells (GEC) demise in NTN. On the one hand, the peptide blunts the p38 pro-inflammatory pathway in GEC, important for the generation of pro-inflammatory mediators, for the induction of eNOS dysfunction and for leukocyte infiltration. On the other hand, TIP peptide protects podocyte barrier function, possibly means by inducing PGE2 generation in podocytes, shown to be protective in NTN. In the early phase of NTN, the peptide blunts systemic generation of TNF, IL-6 and MCP-1, reduces macrophage infiltration, edema formation, restores glomerular filtration rate and synaptopodin expression and abrogates albuminuria. Our central hypothesis is that the TIP peptide protects the kidney against NTN by suppressing TNF-induced activation of pro-inflammatory and barrier-disruptive pathways in GEC and podocytes, respectively, as such blunting leukocyte infiltration and glomerular injury, without interfering with the anti-bacterial actions of the cytokine. In our three specific aims, we
will combine in vivo proof-of-concept NTN mouse studies (aims 1 and 2) podocyte- and GEC-based with mechanistic in vitro cell studies (aim 3). We will use unique models and reagents, such as knock-in mice expressing a TNF mutant without functional lectin-like domain (aim 2). Moreover, we will assess local vs. systemic effects of the peptide upon comparing the efficacy of anti-3(IV) antibody-coupled vs. naked TIP peptide (aim 1A) and testing the peptide in a renal local inflammation model, initiated by endothelial overexpression of transmembrane TNF (aim 1B). Understanding the mechanism of TIP peptide- mediated protective effects against auto-immune GN will advance our knowledge on the inflammatory and anti- inflammatory pathways relevant for nephropathy and will help to conduct clinical trials to determine the efficacy of novel therapeutic peptides against other immune, inflammatory diseases.
描述(由申请人提供):小鼠肾毒性血清(NTS)诱导的肾炎(NTN)的早期特征是过度炎症和肾小球屏障功能障碍,并且代表了人类急性肾小球肾炎(GN)的良好模型。由于它们在白细胞募集、蛋白尿和进行性肾功能衰竭方面发挥着至关重要的作用,因此隔室成为早期治疗干预的有吸引力的目标。治疗或预防疾病进展的方法不足且有限,强调需要控制与 GN 相关的炎症的新治疗方法。在这种情况下,细胞因子 TNF 是一个理想的靶标,因为它与人类 GN 和 GN 密切相关。不幸的是,削弱 TNF 与其受体结合来治疗 GN 的尝试遇到了意想不到的副作用,包括增加细菌感染的风险,因此,专门针对 TNF 的有害作用但保留其有益作用的疗法。我们的初步研究是可取的。一方面,TIP 肽模拟 TNF 的凝集素样结构域,不会干扰配体与其受体的结合,它会干扰 NTN 中足细胞和肾小球内皮细胞 (GEC) 死亡的至少两条重要途径。 ,该肽会削弱 GEC 中的 p38 促炎途径,对于促炎介质的产生、诱导 eNOS 功能障碍以及白细胞都很重要另一方面,TIP 肽可能通过诱导足细胞中 PGE2 的生成来保护足细胞屏障功能,这在 NTN 的早期阶段具有保护作用,该肽会减弱 TNF、IL-6 和 MCP 的全身生成。 -1,减少巨噬细胞浸润、水肿形成,恢复肾小球滤过率和突触蛋白表达,并消除蛋白尿。 TIP 肽通过抑制 TNF 诱导的 GEC 和足细胞中促炎和屏障破坏途径的激活来保护肾脏免受 NTN 侵害,从而减弱白细胞浸润和肾小球损伤,而不干扰 TIP 的抗菌作用在我们的三个具体目标中,我们。
将基于足细胞和 GEC 的体内概念验证 NTN 小鼠研究(目标 1 和 2)与机械体外细胞研究(目标 3)相结合,我们将使用独特的模型和试剂,例如表达敲入小鼠。此外,我们将通过比较抗 α3(IV) 抗体偶联的功效来评估肽的局部与全身效应。与裸 TIP 肽(目标 1A)进行比较,并在由跨膜 TNF 的内皮过度表达引发的肾脏局部炎症模型中测试该肽(目标 1B),了解 TIP 肽介导的针对自身免疫 GN 的保护作用的机制将推进我们的研究。了解与肾病相关的炎症和抗炎途径,将有助于进行临床试验,以确定新型治疗肽针对其他免疫、炎症疾病的功效。
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Cytokine-Ion Channel Interactions in Pulmonary Inflammation.
- DOI:10.3389/fimmu.2017.01644
- 发表时间:2017
- 期刊:
- 影响因子:7.3
- 作者:Hamacher J;Hadizamani Y;Borgmann M;Mohaupt M;Männel DN;Moehrlen U;Lucas R;Stammberger U
- 通讯作者:Stammberger U
Restoration of Epithelial Sodium Channel Function by Synthetic Peptides in Pseudohypoaldosteronism Type 1B Mutants.
- DOI:10.3389/fphar.2017.00085
- 发表时间:2017
- 期刊:
- 影响因子:5.6
- 作者:Willam A;Aufy M;Tzotzos S;Evanzin H;Chytracek S;Geppert S;Fischer B;Fischer H;Pietschmann H;Czikora I;Lucas R;Lemmens-Gruber R;Shabbir W
- 通讯作者:Shabbir W
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rudolf Lucas其他文献
Rudolf Lucas的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rudolf Lucas', 18)}}的其他基金
ENaC-α mediates lung fluid clearance and capillary barrier function in pneumonia
ENaC-α 介导肺炎中的肺液清除和毛细血管屏障功能
- 批准号:
10205151 - 财政年份:2018
- 资助金额:
$ 22.8万 - 项目类别:
ENaC-α mediates lung fluid clearance and capillary barrier function in pneumonia
ENaC-α 介导肺炎中的肺液清除和毛细血管屏障功能
- 批准号:
9976342 - 财政年份:2018
- 资助金额:
$ 22.8万 - 项目类别:
Novel peptide-based strategy to inhibit deleterious TNF signaling in nephrotoxic nephritis
基于肽的新型策略抑制肾毒性肾炎中有害的 TNF 信号传导
- 批准号:
8963148 - 财政年份:2015
- 资助金额:
$ 22.8万 - 项目类别:
Novel peptide-based strategy to inhibit deleterious TNF signaling in nephrotoxic nephritis
基于肽的新型策略抑制肾毒性肾炎中有害的 TNF 信号传导
- 批准号:
9115574 - 财政年份:2015
- 资助金额:
$ 22.8万 - 项目类别:
Protective activity of the lectin-like domain of TNF in permeability edema
TNF 凝集素样结构域对通透性水肿的保护活性
- 批准号:
8111912 - 财政年份:2010
- 资助金额:
$ 22.8万 - 项目类别:
Protective activity of the lectin-like domain of TNF in permeability edema
TNF 凝集素样结构域对通透性水肿的保护活性
- 批准号:
7988150 - 财政年份:2010
- 资助金额:
$ 22.8万 - 项目类别:
Protective activity of the lectin-like domain of TNF in permeability edema
TNF 凝集素样结构域对通透性水肿的保护活性
- 批准号:
8487430 - 财政年份:2010
- 资助金额:
$ 22.8万 - 项目类别:
Protective activity of the lectin-like domain of TNF in permeability edema
TNF 凝集素样结构域对通透性水肿的保护活性
- 批准号:
8308361 - 财政年份:2010
- 资助金额:
$ 22.8万 - 项目类别:
相似国自然基金
儿童药品不良反应主动监测中时序处理策略的方法学研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于真实世界医疗大数据的中西药联用严重不良反应监测与评价关键方法研究
- 批准号:82274368
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于隐狄利克雷分配模型的心血管系统药物不良反应主动监测研究
- 批准号:82273739
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于真实世界数据的创新药品上市后严重罕见不良反应评价关键方法研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
OR10G7错义突变激活NLRP3炎症小体致伊马替尼严重皮肤不良反应的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
相似海外基金
Novel peptide-based strategy to inhibit deleterious TNF signaling in nephrotoxic nephritis
基于肽的新型策略抑制肾毒性肾炎中有害的 TNF 信号传导
- 批准号:
8963148 - 财政年份:2015
- 资助金额:
$ 22.8万 - 项目类别:
Novel peptide-based strategy to inhibit deleterious TNF signaling in nephrotoxic nephritis
基于肽的新型策略抑制肾毒性肾炎中有害的 TNF 信号传导
- 批准号:
9115574 - 财政年份:2015
- 资助金额:
$ 22.8万 - 项目类别:
Topical proprietary biologic to treat oral mucositis
治疗口腔粘膜炎的外用专有生物制剂
- 批准号:
9409310 - 财政年份:2014
- 资助金额:
$ 22.8万 - 项目类别: